Sfoglia per Soggetto "beta 3 adrenergic receptor stimulating agent"
Items 1-5 di 5
-
Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015)
(2017)Aims: To review and assess the definitions of drug resistance and the evidence supporting treatment for drug resistant overactive bladder/detrusor overactivity (OAB/DO). Methods: Evidence review of the extant literature ... -
Desensitization of cAMP accumulation via human β3-adrenoceptors expressed in human embryonic kidney cells by full, partial, and biased agonists
(2019)β3-Adrenoceptors couple not only to cAMP formation but, at least in some cell types, also to alternative signaling pathways such as phosphorylation of extracellular signal-regulated kinase (ERK). β3-Adrenoceptor agonists ... -
Do β3-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?
(2017)[No abstract available] -
New therapeutic strategies for the treatment of male lower urinary tract symptoms
(2016)Male lower urinary tract symptoms (LUTS) are prevalent in the general population, especially in those of advanced age, and are characterized by notable diversity in etiology and presentation, and have been proven to cause ... -
Safety and tolerability of β 3-adrenoceptor agonists in the treatment of overactive bladder syndrome - Insight from transcriptosome and experimental studies
(2016)Introduction: We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. We discuss ...